178 related articles for article (PubMed ID: 27491320)
1. CYP2E1 polymorphisms and nasopharyngeal carcinoma risk: a meta-analysis.
Yao K; Qin H; Gong L; Zhang R; Li L
Eur Arch Otorhinolaryngol; 2017 Jan; 274(1):253-259. PubMed ID: 27491320
[TBL] [Abstract][Full Text] [Related]
2. The PstI/RsaI and DraI polymorphisms of CYP2E1 and head and neck cancer risk: a meta-analysis based on 21 case-control studies.
Tang K; Li Y; Zhang Z; Gu Y; Xiong Y; Feng G; He L; Qin S
BMC Cancer; 2010 Oct; 10():575. PubMed ID: 20969746
[TBL] [Abstract][Full Text] [Related]
3. HLA-DRB1 allele polymorphism and nasopharyngeal carcinoma risk: a meta-analysis.
Yao K; Yang S; Shen J; Zhang R; Li L
Eur Arch Otorhinolaryngol; 2017 Jan; 274(1):297-303. PubMed ID: 27535842
[TBL] [Abstract][Full Text] [Related]
4. Functional PstI/RsaI polymorphism in CYP2E1 is associated with the development, progression and poor outcome of gastric cancer.
Feng J; Pan X; Yu J; Chen Z; Xu H; El-Rifai W; Zhang G; Xu Z
PLoS One; 2012; 7(9):e44478. PubMed ID: 22957075
[TBL] [Abstract][Full Text] [Related]
5. Does CYP2E1 RsaI/PstI polymorphism confer head and neck carcinoma susceptibility?: A meta-analysis based on 43 studies.
Zhuo X; Song J; Liao J; Zhou W; Ye H; Li Q; Xiang Z; Zhang X
Medicine (Baltimore); 2016 Oct; 95(43):e5156. PubMed ID: 27787372
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 2E1 polymorphism and nasopharyngeal carcinoma development in Thailand: a correlative study.
Kongruttanachok N; Sukdikul S; Setavarin S; Kerekhjanarong V; Supiyaphun P; Voravud N; Poovorawan Y; Mutirangura A
BMC Cancer; 2001; 1():4. PubMed ID: 11389775
[TBL] [Abstract][Full Text] [Related]
7. Functional RsaI/PstI polymorphism in cytochrome P450 2E1 contributes to bladder cancer susceptibility: evidence from a meta-analysis.
Deng XD; Gao Q; Zhang B; Zhang LX; Zhang W; Mu Er ZE; Xie Y; Ma Y; Liu Y
Asian Pac J Cancer Prev; 2014; 15(12):4977-82. PubMed ID: 24998574
[TBL] [Abstract][Full Text] [Related]
8. CYP2E1 PstI polymorphism increases cervical neoplasia risk: a meta-analysis.
Wang X; He Y
Genet Mol Res; 2015 May; 14(2):5203-9. PubMed ID: 26125714
[TBL] [Abstract][Full Text] [Related]
9. CYP2E1 RsaI/PstI polymorphisms contributed to oral cancer susceptibility: a meta-analysis.
Guo Y; Zhou S; Liu F; Zhang B
Int J Clin Exp Pathol; 2015; 8(11):14685-92. PubMed ID: 26823792
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphism in cytochrome P450 2E1 and alcoholic pancreatitis sus-ceptibility: a meta-analysis.
Wu C; Wu D; Liu Y; Zhong Y
Hippokratia; 2018; 22(2):60-67. PubMed ID: 31217677
[TBL] [Abstract][Full Text] [Related]
11. Impact of CYP2E1 genotype in renal cell and urothelial cancer patients.
Farker K; Lehmann MH; Oelschlägel B; Haerting J; Hoffmann A; Janitzky V; Schubert J
Exp Toxicol Pathol; 1998 Sep; 50(4-6):425-31. PubMed ID: 9784018
[TBL] [Abstract][Full Text] [Related]
12. CYP2E1 RsaI/PstI polymorphism and risk of anti-tuberculosis drug-induced liver injury: a meta-analysis.
Deng R; Yang T; Wang Y; Tang N
Int J Tuberc Lung Dis; 2012 Dec; 16(12):1574-81. PubMed ID: 23131254
[TBL] [Abstract][Full Text] [Related]
13. Update meta-analysis of the CYP2E1 RsaI/PstI and DraI polymorphisms and risk of antituberculosis drug-induced hepatotoxicity: evidence from 26 studies.
Wang FJ; Wang Y; Niu T; Lu WX; Sandford AJ; He JQ
J Clin Pharm Ther; 2016 Jun; 41(3):334-40. PubMed ID: 27062377
[TBL] [Abstract][Full Text] [Related]
14. Updated meta-analysis of the association between CYP2E1 RsaI/PstI polymorphisms and lung cancer risk in Chinese population.
Wang YD; Yang HY; Liu J; Wang HY
Asian Pac J Cancer Prev; 2014; 15(13):5411-6. PubMed ID: 25040958
[TBL] [Abstract][Full Text] [Related]
15. CYP2E1 PstI/RsaI polymorphism and colorectal cancer risk: a meta-analysis.
Zhou GW; Hu J; Li Q
World J Gastroenterol; 2010 Jun; 16(23):2949-53. PubMed ID: 20556843
[TBL] [Abstract][Full Text] [Related]
16. CYP2E1 RsaI/PstI polymorphism and gastric cancer susceptibility: meta-analyses based on 24 case-control studies.
Zhuo W; Zhang L; Wang Y; Ling J; Zhu B; Chen Z
PLoS One; 2012; 7(11):e48265. PubMed ID: 23139769
[TBL] [Abstract][Full Text] [Related]
17. CYP2E1 genotyping in renal cell/urothelial cancer patients in comparison with control populations.
Farker K; Lehmann MH; Kästner R; Hoffmann A; Janitzky V; Schubert J; Matz U; Hofmann W
Int J Clin Pharmacol Ther; 1998 Sep; 36(9):463-8. PubMed ID: 9760005
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of cytochrome P450 2E1 RsaI/PstI and DraI polymorphisms in workers exposed to benzene].
Chen Z; Ling J; Liu Y; Wu X; Wang D; Wang J; Tu H
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2015 Aug; 33(8):595-7. PubMed ID: 26653810
[TBL] [Abstract][Full Text] [Related]
19. Association between the CYP2E1 polymorphisms and lung cancer risk: a meta-analysis.
Ye XH; Song L; Peng L; Bu Z; Yan SX; Feng J; Zhu XL; Liao XB; Yu XL; Yan D
Mol Genet Genomics; 2015 Apr; 290(2):545-58. PubMed ID: 25336053
[TBL] [Abstract][Full Text] [Related]
20. Association between CYP2E1 genetic polymorphisms and lung cancer risk: a meta-analysis.
Wang Y; Yang H; Li L; Wang H; Zhang C; Yin G; Zhu B
Eur J Cancer; 2010 Mar; 46(4):758-64. PubMed ID: 20031389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
